Therapeutic DC vaccination with IL-2 as a consolidation therapy for ovarian cancer patients: A phase I/II trial

Cellular and Molecular Immunology

Volumn 12, Issue 1, 2015, Pages 87-95

  Baek, Soyoung ^a   Kim, Yong Man ^b,c   Kim, Sung Bae ^b   Kim, Choung Soo ^b   Kwon, Seog Woon ^b   Kim, Hyun Soo ^c   Lee, Hyunah ^a  

^a Sungkyunkwan University   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

^c FCB Pharmicell CoLtd   (South Korea)

Author keywords

dendritic cell vaccine; immune response; ovarian cancer; phase I II trial

Indexed keywords

DENDRITIC CELL VACCINE; INTERLEUKIN 2; CANCER VACCINE; GAMMA INTERFERON; HEMOCYANIN; KEYHOLE-LIMPET HEMOCYANIN; TUMOR ANTIGEN;

ADULT; ARTICLE; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CONSOLIDATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE FREE SURVIVAL; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEASIBILITY STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOMODULATION; LONG TERM SURVIVAL; LOW DRUG DOSE; MIDDLE AGED; NATURAL KILLER CELL; OVARY CANCER; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; T LYMPHOCYTE; CLINICAL TRIAL; DENDRITIC CELL; FOLLOW UP; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; MULTICENTER STUDY; OVARIAN NEOPLASMS; PROCEDURES; RECURRENT DISEASE; TRANSPLANTATION; TREATMENT OUTCOME;

ADULT; ANTIGENS, NEOPLASM; CANCER VACCINES; CONSOLIDATION CHEMOTHERAPY; DENDRITIC CELLS; FEMALE; FOLLOW-UP STUDIES; HEMOCYANIN; HUMANS; IMMUNOTHERAPY; INTERFERON-GAMMA; INTERLEUKIN-2; KILLER CELLS, NATURAL; MIDDLE AGED; OVARIAN NEOPLASMS; RECURRENCE; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 84920540809     PISSN: 16727681     EISSN: None     Source Type: Journal    
DOI: 10.1038/cmi.2014.40     Document Type: Article

References (27)

1. Ozols RF, Bookman MA, Connolly DC, Daly MB, Godwin AK, Schilder RJ et al. Focus on epithelial ovarian cancer. Cancer Cell 2004; 5: 19-24
2. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin 1999; 49: 8-31
3. Wagner U, Kohler S, Reinartz S, Giffels P, Huober J, Renke K et al. Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: immune responses and survival in palliative treatment. See The biology behind: K. A. Foon and M. Bhattacharya-Chatterjee, Are solid tumor anti-idiotype vaccines ready for prime time?. Clin. Cancer Res., 7:1112-1115, 2001. Clin Cancer Res 2001; 7: 1154-1162
4. Cannon MJ, Santin AD, O'Brien TJ. Immunological treatment of ovarian cancer. Curr Opin Obstet Gynecol 2004; 16: 87-92
5. Paczesny S, Banchereau J, Wittkowski KM, Saracino G, Fay J, Palucka AK. Expansion of melanoma-specific cytolytic CD81 T cell precursors in patients with metastatic melanoma vaccinated with CD341 progenitor-derived dendritic cells. J Exp Med 2004; 199: 1503-1511
6. Kim JH, Lee Y, Bae YS, Kim WS, Kim K, Im HY et al. Phase I/II study of immunotherapy using autologous tumor lysate-pulsed dendritic cells in patients with metastatic renal cell carcinoma. Clin Immunol 2007; 125: 257-267
7. Baek S, Kim CS, Kim SB, Kim YM, Kwone SW, Kim Y et al. Combination therapy of renal cell carcinoma or breast cancer patients with dendritic cell vaccine and IL-2: results from a phase I/II trial. J Transl Med 2011; 9: 178
8. Ragde H, Cavanagh WA, Tjoa BA. Dendritic cell based vaccines: progress in immunotherapy studies for prostate cancer. J Urol 2004; 172: 2532-2538
9. Iwashita Y, Tahara K, Goto S, Sasaki A, Kai S, Seike M et al. A phase I study of autologous dendritic cell-based immunotherapy for patients with unresectable primary liver cancer. Cancer Immunol Immunother 2003; 52: 155-161
10. Chu CS, Boyer J, Schullery DS, Gimotty PA, Gamerman V, Bender J et al. Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission. Cancer Immunol Immunother 2012; 61: 629-641
11. Kandalaft LE, Powell Jr DJ, Chiang CL, Tanyi J, Kim S, Bosch Met al. Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer. Oncoimmunology 2013; 2: e22664
12. Rahma OE, Ashtar E, Czystowska M, Szajnik ME, Wieckowski E, Bernstein S et al. A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients. Cancer Immunol Immunother 2012; 61: 373-384
13. Bernal SD, Ona ET, Riego-Javier A, R DEV, Cristal-Luna GR, Laguatan JB et al. Anticancer immune reactivity and long-term survival after treatment of metastatic ovarian cancer with dendritic cells. Oncol Lett 2012; 3: 66-74
14. Rosenberg SA, Grimm EA, McGrogan M, Doyle M, Kawasaki E, Koths K et al. Biological activity of recombinant human interleukin-2 produced in Escherichia coli. Science 1984; 223: 1412-1414
15. Hiura T, Kagamu H, Miura S, Ishida A, Tanaka H, Tanaka J et al. Both regulatory T cells and antitumor effector T cells are primed in the same draining lymph nodes during tumor progression. J Immunol 2005; 175: 5058-5066
16. Knoechel B, Lohr J, Kahn E, Bluestone JA, Abbas AK. Sequential development of interleukin 2-dependent effector and regulatory T cells in response to endogenous systemic antigen. J Exp Med 2005; 202: 1375-1386
17. Lissoni P. Effects of low-dose recombinant interleukin-2 in human malignancies. Cancer J Sci Am 1997; 3(Suppl 1): S115-S120
18. Steinman RM, Banchereau, J. Taking dendritic cells into medicine. Nature 2007; 449: 419-426
19. Engell-Noerregaard L, Hansen TH, Andersen MH, Thor Straten P, Svane IM. Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: Assessment of correlation between clinical response and vaccine parameters. Cancer Immunol Immunother 2009; 58: 1-14
20. Handa K, Suzuki R, Matsui H, Shimizu Y, Kumagai K. Natural killer (NK) cells as a responder to interleukin 2 (IL 2). II. IL 2-induced interferon gamma production. J Immunol 1983; 130: 988-992
21. Antony GK, Dudek AZ. Interleukin 2 in cancer therapy. Curr Med Chem 2010; 17: 3297-3302
22. Antony PA, Restifo NP. CD41CD251 T regulatory cells, immunotherapy of cancer, and interleukin-2. J Immunother 2005; 28: 120-128
23. Cesana GC, DeRaffele G, Cohen S, Moroziewicz D, Mitcham J, Stoutenburg J et al. Characterization of CD41CD251 regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin Oncol 2006; 24: 1169-1177
24. Ahmadzadeh M, Rosenberg SA. IL-2 administration increases CD41 CD25hi Foxp31 regulatory T cells in cancer patients. Blood 2006; 107: 2409-2414
25. deLeeuw RJ, Kost SE, Kakal JA, Nelson BH. The prognostic value of FoxP31 tumor-infiltrating lymphocytes in cancer: A critical review of the literature. Clin Cancer Res 2012; 18: 3022-3029
26. Saito H, Tsujitani S, Oka S, Kondo A, Ikeguchi M, Maeta M et al. The expression of transforming growth factor-beta1 is significantly correlated with the expression of vascular endothelial growth factor and poor prognosis of patients with advanced gastric carcinoma. Cancer 1999; 86: 1455-1462
27. Kassim SK, El-Salahy EM, Fayed ST, Helal SA, Helal T, Azzam Eel D et al. Vascular endothelial growth factor and interleukin-8 are associated with poor prognosis in epithelial ovarian cancer patients. Clin Biochem 2004; 37: 363-369